CyclASol: Completed Phase II enrollment

Novaliq completed enrollment of 207 patients with moderate to severe dry eye syndrome in a double-blind, placebo-controlled, U.S. Phase II trial comparing 2 dose levels of twice-daily topical CyclASol...